New treatment options for noninfectious uveitis

Millena Gomes Bittencourt, Yasir Jamal Sepah, Diana V. Do, Owhofasa Agbedia, Abeer Akhtar, Hongting Liu, Anam Akhlaq, Rachel Annam, Mohamed Ibrahim, Quan Dong Nguyen

Research output: Chapter in Book/Report/Conference proceedingChapter

24 Citations (Scopus)

Abstract

Autoimmune uveitis is a group of sight-threatening inflammatory diseases associated with an exacerbated immunological response to ocular proteins. The Standardization of Uveitis Nomenclature Working Group Guidelines have recommended the use of corticosteroids as the first line of therapy for patients who present with active uveitis. However, long-term use of corticosteroids is associated with numerous adverse effects including cataract, glaucoma and metabolic disorders. In this context, new drugs developed to treat rheumatic diseases, and other autoimmune diseases, are being employed often as monotherapy or combined with other immunosuppressive drugs in order to decrease the corticosteroid burden on patients and to manage refractive uveitis. These drugs are currently being evaluated in the framework of uveitis and may open a new horizon with less side effects and more responsiveness for chronic cases. Among others, calcineurin inhibitor voclosporin, mammalian target of rapamycin inhibitor sirolimus, and the IL-1 trap rilonacept, are among these new agents and will be scrutinized in detail in this chapter. More efficient modes of drug delivery are also being employed to deliver high concentration of drug locally and to minimize systemic side effects. The new modes of drug delivery that we will describe in the index chapter include nanoparticles and iontophoresis.

Original languageEnglish (US)
Title of host publicationNew Treatments in Noninfectious Uveitis
EditorsElisabetta Miserocchi, Giulio Modorati, Stephen Foster
Pages134-161
Number of pages28
DOIs
StatePublished - Apr 1 2012

Publication series

NameDevelopments in Ophthalmology
Volume51
ISSN (Print)0250-3751
ISSN (Electronic)1662-2790

Fingerprint

Uveitis
Pharmaceutical Preparations
Adrenal Cortex Hormones
Sirolimus
Eye Proteins
Therapeutics
Iontophoresis
Immunosuppressive Agents
Rheumatic Diseases
Interleukin-1
Terminology
Glaucoma
Nanoparticles
Cataract
Autoimmune Diseases
Guidelines

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Gomes Bittencourt, M., Sepah, Y. J., Do, D. V., Agbedia, O., Akhtar, A., Liu, H., ... Nguyen, Q. D. (2012). New treatment options for noninfectious uveitis. In E. Miserocchi, G. Modorati, & S. Foster (Eds.), New Treatments in Noninfectious Uveitis (pp. 134-161). (Developments in Ophthalmology; Vol. 51). https://doi.org/10.1159/000336338

New treatment options for noninfectious uveitis. / Gomes Bittencourt, Millena; Sepah, Yasir Jamal; Do, Diana V.; Agbedia, Owhofasa; Akhtar, Abeer; Liu, Hongting; Akhlaq, Anam; Annam, Rachel; Ibrahim, Mohamed; Nguyen, Quan Dong.

New Treatments in Noninfectious Uveitis. ed. / Elisabetta Miserocchi; Giulio Modorati; Stephen Foster. 2012. p. 134-161 (Developments in Ophthalmology; Vol. 51).

Research output: Chapter in Book/Report/Conference proceedingChapter

Gomes Bittencourt, M, Sepah, YJ, Do, DV, Agbedia, O, Akhtar, A, Liu, H, Akhlaq, A, Annam, R, Ibrahim, M & Nguyen, QD 2012, New treatment options for noninfectious uveitis. in E Miserocchi, G Modorati & S Foster (eds), New Treatments in Noninfectious Uveitis. Developments in Ophthalmology, vol. 51, pp. 134-161. https://doi.org/10.1159/000336338
Gomes Bittencourt M, Sepah YJ, Do DV, Agbedia O, Akhtar A, Liu H et al. New treatment options for noninfectious uveitis. In Miserocchi E, Modorati G, Foster S, editors, New Treatments in Noninfectious Uveitis. 2012. p. 134-161. (Developments in Ophthalmology). https://doi.org/10.1159/000336338
Gomes Bittencourt, Millena ; Sepah, Yasir Jamal ; Do, Diana V. ; Agbedia, Owhofasa ; Akhtar, Abeer ; Liu, Hongting ; Akhlaq, Anam ; Annam, Rachel ; Ibrahim, Mohamed ; Nguyen, Quan Dong. / New treatment options for noninfectious uveitis. New Treatments in Noninfectious Uveitis. editor / Elisabetta Miserocchi ; Giulio Modorati ; Stephen Foster. 2012. pp. 134-161 (Developments in Ophthalmology).
@inbook{5d1d31876339499b9b57c1ba0cbac79d,
title = "New treatment options for noninfectious uveitis",
abstract = "Autoimmune uveitis is a group of sight-threatening inflammatory diseases associated with an exacerbated immunological response to ocular proteins. The Standardization of Uveitis Nomenclature Working Group Guidelines have recommended the use of corticosteroids as the first line of therapy for patients who present with active uveitis. However, long-term use of corticosteroids is associated with numerous adverse effects including cataract, glaucoma and metabolic disorders. In this context, new drugs developed to treat rheumatic diseases, and other autoimmune diseases, are being employed often as monotherapy or combined with other immunosuppressive drugs in order to decrease the corticosteroid burden on patients and to manage refractive uveitis. These drugs are currently being evaluated in the framework of uveitis and may open a new horizon with less side effects and more responsiveness for chronic cases. Among others, calcineurin inhibitor voclosporin, mammalian target of rapamycin inhibitor sirolimus, and the IL-1 trap rilonacept, are among these new agents and will be scrutinized in detail in this chapter. More efficient modes of drug delivery are also being employed to deliver high concentration of drug locally and to minimize systemic side effects. The new modes of drug delivery that we will describe in the index chapter include nanoparticles and iontophoresis.",
author = "{Gomes Bittencourt}, Millena and Sepah, {Yasir Jamal} and Do, {Diana V.} and Owhofasa Agbedia and Abeer Akhtar and Hongting Liu and Anam Akhlaq and Rachel Annam and Mohamed Ibrahim and Nguyen, {Quan Dong}",
year = "2012",
month = "4",
day = "1",
doi = "10.1159/000336338",
language = "English (US)",
isbn = "9783805599863",
series = "Developments in Ophthalmology",
pages = "134--161",
editor = "Elisabetta Miserocchi and Giulio Modorati and Stephen Foster",
booktitle = "New Treatments in Noninfectious Uveitis",

}

TY - CHAP

T1 - New treatment options for noninfectious uveitis

AU - Gomes Bittencourt, Millena

AU - Sepah, Yasir Jamal

AU - Do, Diana V.

AU - Agbedia, Owhofasa

AU - Akhtar, Abeer

AU - Liu, Hongting

AU - Akhlaq, Anam

AU - Annam, Rachel

AU - Ibrahim, Mohamed

AU - Nguyen, Quan Dong

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Autoimmune uveitis is a group of sight-threatening inflammatory diseases associated with an exacerbated immunological response to ocular proteins. The Standardization of Uveitis Nomenclature Working Group Guidelines have recommended the use of corticosteroids as the first line of therapy for patients who present with active uveitis. However, long-term use of corticosteroids is associated with numerous adverse effects including cataract, glaucoma and metabolic disorders. In this context, new drugs developed to treat rheumatic diseases, and other autoimmune diseases, are being employed often as monotherapy or combined with other immunosuppressive drugs in order to decrease the corticosteroid burden on patients and to manage refractive uveitis. These drugs are currently being evaluated in the framework of uveitis and may open a new horizon with less side effects and more responsiveness for chronic cases. Among others, calcineurin inhibitor voclosporin, mammalian target of rapamycin inhibitor sirolimus, and the IL-1 trap rilonacept, are among these new agents and will be scrutinized in detail in this chapter. More efficient modes of drug delivery are also being employed to deliver high concentration of drug locally and to minimize systemic side effects. The new modes of drug delivery that we will describe in the index chapter include nanoparticles and iontophoresis.

AB - Autoimmune uveitis is a group of sight-threatening inflammatory diseases associated with an exacerbated immunological response to ocular proteins. The Standardization of Uveitis Nomenclature Working Group Guidelines have recommended the use of corticosteroids as the first line of therapy for patients who present with active uveitis. However, long-term use of corticosteroids is associated with numerous adverse effects including cataract, glaucoma and metabolic disorders. In this context, new drugs developed to treat rheumatic diseases, and other autoimmune diseases, are being employed often as monotherapy or combined with other immunosuppressive drugs in order to decrease the corticosteroid burden on patients and to manage refractive uveitis. These drugs are currently being evaluated in the framework of uveitis and may open a new horizon with less side effects and more responsiveness for chronic cases. Among others, calcineurin inhibitor voclosporin, mammalian target of rapamycin inhibitor sirolimus, and the IL-1 trap rilonacept, are among these new agents and will be scrutinized in detail in this chapter. More efficient modes of drug delivery are also being employed to deliver high concentration of drug locally and to minimize systemic side effects. The new modes of drug delivery that we will describe in the index chapter include nanoparticles and iontophoresis.

UR - http://www.scopus.com/inward/record.url?scp=84860847076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860847076&partnerID=8YFLogxK

U2 - 10.1159/000336338

DO - 10.1159/000336338

M3 - Chapter

C2 - 22517211

AN - SCOPUS:84860847076

SN - 9783805599863

T3 - Developments in Ophthalmology

SP - 134

EP - 161

BT - New Treatments in Noninfectious Uveitis

A2 - Miserocchi, Elisabetta

A2 - Modorati, Giulio

A2 - Foster, Stephen

ER -